A hypoxia-inducible vigilant vector system for activating therapeutic genes in ischemia

Gene Therapy

Volumn 12, Issue 15, 2005, Pages 1163-1170

  Tang, Y L ^a   Tang, Y ^b   Zhang, Y C ^a   Agarwal, A ^c   Kasahara, H ^d   Qian, K ^a   Shen, L ^a   Phillips, M I ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b AnaSpec Inc   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Heart myocardial ischemia; Hypoxia; Ischemic diseases; Regulatable gene delivery

Indexed keywords

HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; GENE SWITCHING; GENE TRANSFER; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; HYPOXIA; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; STROKE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANOXIA; APOPTOSIS; CELLS, CULTURED; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, SWITCH; GENETIC ENGINEERING; GENETIC VECTORS; HEME OXYGENASE-1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 23744451791     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302513     Document Type: Article

References (41)

1. Semenza GL et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol 2000; 475: 123-130.
2. Acker T, Plate KH. A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J Mol Med 2002; 80: 562-575.
3. Khan TA, Selke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Therapy 2003; 10: 285-291.
4. Lee RJ et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
5. Springer ML et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998; 2: 549-558.
6. Binley K et al. Hypoxia-mediated tumour targeting. Gene Therapy 2003; 10: 540-549.
7. Greco O et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy 2002; 9: 1403-1411.
8. Su H, Arakawa-Hoyt J, Kan YW. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci USA 2002; 99: 9480-9485.
9. Ido A et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res 2001; 61: 3016-3021.
10. Boast K et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999; 10: 2197-2208.
11. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721-1727.
12. Ruan et al. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 2001; 3: 255-263.
13. Bainbridge JW et al. Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization. Gene Therapy 2003; 10: 1049-1054.
14. Binley K et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002; 100: 2406-2413.
15. Prentice H et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc Res 1997; 35: 567-574.
16. Tang Y, Jackson M, Qian K, Phillips MI. Hypoxia inducible double plasmid system for myocardial ischemia gene therapy. Hypertension 2002; 39: 695-698.
17. Phillips M et al. Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 2002; 39: 651-655.
18. Pachori AS et al. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci USA 2004; 101: 12282-12287.
19. Tang Y et al. Vigilant vectors: adeno-associated virus with a biosensor to switch on amplified therapeutic genes in specific tissues in life-threatening diseases. Methods 2002; 28: 259-266.
20. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001; 13: 167-171.
21. Salnikow K, Su W, Blagosklonny MV, Costa M. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res 2000; 60: 3375-3378.
22. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000; 275: 26765-26771.
23. Sandau KB, Fandrey J, Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 2001; 97: 1009-1015.
24. Stroka DM et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001; 15: 2445-2453.
25. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 7987-7992.
26. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 2000; 97: 4748-4753.
27. Wang Y, O'Malley Jr BW, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA. 1994; 91: 8180-8184.
28. O'Brien TX, Lee KJ, Chien KR. Positional specification of ventricular myosin light chain 2 expression in the primitive murine heart tube. Proc Natl Acad Sci USA 1993; 90: 5157-5161.
29. Mathey DG, Sheehan FH, Schofer J, Dodge HT. Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute transmural infarction. J Am Coll Cardiol 1985; 6: 518-525.
30. Heyndrickx GR et al. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol 1978; 234: H653-H659.
31. Rumsey WL, Pawlowski M, Lejavardi N, Wilson DF. Oxygen pressure distribution in the heart in vivo and evaluation of the ischemic 'border zone'. Am J Physiol 1994; 266: H1676-H1680.
32. Dekker M. Oxygenation of solid tumours. In: Teicher BA (ed). Drug Resistance in Oncology. Marcel Dekker, Inc.: New York, 1993.
33. Melo LG et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002; 105: 602-607.
34. Vulapalli SR et al. Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. Am J Physiol Heart Circ Physiol 2002; 283: H688-H694.
35. Yet SF et al. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J 2003; 17: 1759-1761.
36. Yet SF et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 2001; 89: 168-173.
37. Tang YL et al. Protection from ischemic heart injury by a vigilant heme oxygenase-1 plasmid system. Hypertension 2004; 43: 746-751.
38. Duan D, Yue Y, Yan Z, Engelhardt JF. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000; 6: 595-598.
39. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000; 6: 599-602.
40. Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 2000; 18: 527-532.
41. Rendahl KG et al. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biotechnol 1998; 16: 757-761.